Acute Promyelocytic Leukemia (PML-RARA) · line 1 · ATRA + ATO + Idarubicin (APL high-risk) — modified APL0406 / AIDA-style
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-ATRA-ATO-IDA-APL |
| ID | IND-APL-1L-ATRA-ATO-IDA |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-APL |
| Sources | SRC-ELN-APL-2019 SRC-NCCN-AML-2025 |
Notes
AGGRESSIVE track for high-risk APL. time_critical: true (see IND-APL-1L-ATRA-ATO notes). LVEF assessment + cumulative anthracycline tracking + cardiac follow-up post-treatment. STUB — requires clinical co-lead signoff.
Used By
Algorithms
ALGO-APL-1L- ALGO-APL-1L